AstraZeneca (AZN) Stock Forecast & Price Target

$77.32

-0.12 (-0.15%)

(As of 10/22/2024 ET)

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
1

Hold
1

Buy
9

Based on 11 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a sell rating, 1 has given a hold rating, 7 have given a buy rating, and 2 have given a strong buy rating for AZN.

Consensus Price Target

$89.75
16.08% Upside

According to the 11 analysts' twelve-month price targets for AstraZeneca, the average price target is $89.75. The highest price target for AZN is $97.00, while the lowest price target for AZN is $82.00. The average price target represents a forecasted upside of 16.08% from the current price of $77.32.

Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

AZN Analyst Ratings Over Time

Type	Current Forecast 10/24/23 to 10/23/24	1 Month Ago 9/24/23 to 9/23/24	3 Months Ago 7/26/23 to 7/25/24	1 Year Ago 10/24/22 to 10/24/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$89.75	$89.75	$88.00	$80.00
Forecasted Upside	16.08% Upside	16.35% Upside	12.07% Upside	23.90% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Are You Holding the Winning Hand in the Copper Market? (Ad)

Are You Holding the Winning Hand in the Copper Market?

Click here to learn more about this copper stock before the market catches on.

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca Stock vs. The Competition

Type	AstraZeneca	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	16.08% Upside	8,463.81% Upside	7.90% Upside
News Sentiment Rating	Positive News See Recent AZN News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/13/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Downgrade	Hold ➝ Sell
9/11/2024	Erste Group Bank 3 of 5 stars		Upgrade	Hold ➝ Buy
8/12/2024	TD Cowen 4 of 5 stars		Boost Target	Buy ➝ Buy	$90.00 ➝ $95.00	+16.29%
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $85.00	+10.72%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$97.00	+27.50%
4/26/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$80.00 ➝ $82.00	+8.70%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight
1/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
12/18/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
7/12/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
1/18/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		GBX 118 ➝ GBX 126

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:25 AM ET.

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 18, 2024. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca:

AstraZeneca has a strong buy rating from multiple analysts, indicating positive sentiment towards the company's future performance.
The company's recent stock price of $77.35 presents a potential buying opportunity for investors looking to enter at a relatively lower price point.
AstraZeneca's focus on the discovery, development, and commercialization of prescription medicines positions it well in the biopharmaceutical industry, which has shown resilience and growth potential.
The company's consistent revenue growth and solid financial performance, with a net margin of 13.11% and a return on equity of 29.34%, demonstrate operational strength.
AstraZeneca's dividend yield of 1.8% provides investors with a source of passive income, adding to the total return on investment.

AstraZeneca
Bear Case

Investors should be bearish about investing in AstraZeneca for these reasons:

Despite some positive ratings, there are also sell ratings on AstraZeneca, indicating a level of uncertainty or risk associated with the company's performance.
The company's stock price has experienced fluctuations, with a 12-month low of $60.47 and a high of $87.68, suggesting potential volatility in the stock.
AstraZeneca's PEG ratio of 1.43 may indicate that the stock is currently overvalued based on its growth prospects, potentially limiting upside potential for investors.
Market conditions and regulatory changes in the pharmaceutical industry could impact AstraZeneca's future revenue and profitability, leading to uncertainties for investors.
Investors should consider the competitive landscape and potential challenges in drug development and commercialization that AstraZeneca may face, affecting its long-term growth prospects.

AZN Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $89.75, with a high forecast of $97.00 and a low forecast of $82.00.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There is currently 1 sell rating, 1 hold rating, 7 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AZN shares.
: According to analysts, AstraZeneca's stock has a predicted upside of 16.08% based on their 12-month stock forecasts.
: Over the previous 90 days, AstraZeneca's stock had 1 upgrade and 1 downgrade by analysts.
: AstraZeneca has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Erste Group Bank, and TD Cowen in the past 90 days.
: Analysts like AstraZeneca more than other "medical" companies. The consensus rating score for AstraZeneca is 2.91 while the average consensus rating score for "medical" companies is 2.79. Learn more on how AZN compares to other companies.